Few things epitomize the European Medicines Agency (EMA) as much as its now 30-year-old centralized procedure for approving human medicines. With one submission and one evaluation, a medicine can be authorized simultaneously in all 27 European Union (EU) member states.
As the EMA marks its 30th anniversary in 2025 with a year-long series of events at its offices in Amsterdam, it will be reflecting on the far-reaching achievements of the centralized procedure. But it is also a moment for renewed advocacy for international cooperation.
